AGIOAgios Pharmaceuticals, Inc.

$31.83-16% 1Y

$31.83

$22.3452 weeks$45.49

AGIO in its own filings

Nothing in AGIO's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

279

Events found in the filings · across 1,297 filings · the record starts in 2013

Hard flags: none
Hard flags
Most recent filing: Jul 30, 2026
Most recent filing · Form 10-Q
Record starts: Jun 20, 2013
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 29, 2026
Change in certifying accountanthistorical: 2017-05-05
SEC comment-letter activity14 occurrences: 2024-06-24

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Jul 30, 2026Agios Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Jun 18, 2026At the 2026 Annual Meeting of Stockholders of Agios Pharmaceuticals, Inc. (the “Company”) held on June 18, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2023 Plan Amendment”) to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan (the “Current Plan”)Director or officer change · Form 8-K
Apr 29, 2026Agios Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Feb 12, 2026Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
Jan 12, 2026Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth.Regulation FD disclosure · press release
Oct 30, 2025Agios Reports Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release